Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 3

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Peripheral antinociceptive effect of biphalin in a mouse model of cancer pain

100%
Lesniak A., Bochynska-Czyz M., Sacharczuk M., Lipkowski A. W.
Acta Neurobiologiae Experimentalis
|
2013
|
tom 73
|
nr 1
It is generally accepted that classical opioids exert their antinociceptive effect mainly when binding to opioid receptors located in the central nervous system. However, a growing body of evidence points to the relevance of peripheral opioid receptors in periphery pathology, including cancer. A cancer is very often the cause of pain resulting from peripheral metastasis. The peripheral component of antinociception induced by a dimeric enkephalin analog – biphalin showing limited blood-brainbarrier permeability may prove important in cancer pain therapy. An additional advantage of biphalin is a possibility to treat pain symptoms with reduction of side-effects – a result of the central action of some other opioid analgesics, e.g. morphine. We examined the peripheral and central analgesic effect of biphalin in a murine skin cancer pain model developed by an intraplantar inoculation of B16T0 melanoma cells. Animals developed robust thermal hypersensitivity in the tumor-bearing paw compared to PBS-injected individuals. Biphalin produced stronger analgesia in the tumor-bearing paw than morphine upon a comparable central effect. Our results suggest that biphalin analgesia manifested in the periphery is linked to a less effective transport through the bloodbrain barrier. We speculate that the centrally effective dose of biphalin equipotent to morphine simultaneously produces analgesia via peripheral opioid receptors. Thus, biphalin may become useful in cancer pain treatment as an alternative drug executing a local as well as a central analgesic response with limited undesirable side-effects.
2

Synthesis and cell cancer growth inhibiting properties of somatostatin analogs

100%
Dyniewicz J., Bochynska-Czyz M., Lipkowski A. W.
Acta Neurobiologiae Experimentalis
|
2011
|
tom 71
|
nr 1
Somatostatin (SST) is a tetradecapeptide that was originally characterized as a physiological inhibitor of growth hormone. In addition, SST has another multiple functions. It regulates endocrine and exocrine secretion, possesses antiproliferative properties and acts as a neurotransmitter/neuromodulator. These diverse physiological effects are mediated by a family of G-protein-coupled receptors, called somatostatin receptors sst1 - sst5. Nowadays, there are several cyclic synthetic somatostatin analogues (eg octreotide, lanreotide), clinically used for cancer therapy and gastrointestinal disorders, that primarily interact with receptor sst2 and sst5. Our goal is to synthesize a linear tetrapeptide which would have activity like somatostatin. The base of analogs’ structures are, key for somatostatin activity, aminoacids residues like. Results of this experiments will be present on the poster.
3

Opioid peptides in peripheral pain control

76%
Lesniak A., Sacharczuk M., Kosson P., Bochynska-Czyz M., Szaniawska B., Lipkowski A. W.
Acta Neurobiologiae Experimentalis
|
2011
|
tom 71
|
nr 1
Malignant, long-lasting pain is an imminent component in advanced cancer and as such sufficiently decreases the quality of life of patients. Cancer patients are equally subjected to physical as well as emotional suffering. For many decades opioids have been the mainstay analgesics for treatment of moderate to severe pain conditions. Classical opioids by exerting their analgesic action in the CNS apart from producing analgesia simultaneously cause the onset of undesirable side effects such as constipation, nausea or sedation. The major advantage is a possibility to treat pain symptoms with avoidance of minor side-effects, particularly tolerance occurring in morphine-treated patients. In clinical practice it is important for a drug to possess both a peripheral and central action. In our studies we examined the analgesic effect of a dimeric enkephalin analog-biphalin in a murine skin cancer pain model developed by an intraplantar inoculation of B16T0 melanoma cells. Animals developed robust thermal hypersensitivity in the tumor-bearing paw compared to saline-injected individuals. Biphalin produced a more robust unilateral attenuation of thermal hyperalgesia in the tumor-bearing paw as compared to the classical non-peptidic drugmorphine. Results suggest a probable involvement of the peripheral opioid receptor-mediated analgesia. Thus, biphalin, may become a useful drug in cancer pain treatment because it also shows low tolerance liability. Financial support: 6FP STREP Normolife grant (LSHC-CT-2006- 037733)
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.